Join the club for FREE to access the whole archive and other member benefits.

Biogen

Company specialized in the discovery, development, and delivery of therapies for the treatment of neurological diseases

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.

Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.

With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

Visit website: https://www.biogen.com/

 Biogen

 biogen-

 biogen

 biogen

Details last updated 28-Sep-2019

People at Biogen

Michel Vounatsos

Chief Executive Officer at Biogen

Alfred Sandrock

EVP, R&D and Chief Medical Officer at Biogen.

Biogen News

The future of longevity: investing in the next biotech revolution

The future of longevity: investing in the next biotech revolution

The Motley Fool - 13-Aug-2024

How lifespan-extending drugs could shape the next biotech boom

Biogen discontinues controversial Alzheimer's drug Aduhelm

Biogen discontinues controversial Alzheimer's drug Aduhelm

Independent - 31-Jan-2024

Once hailed as a breakthrough, Aduhelm faces final curtain after limited use and insurance hurdles

Eisai's Lecanemab drug proves to slowdown Alzheimer's disease, unlike aducanumab drug

Eisai's Lecanemab drug proves to slowdown Alzheimer's disease, unlike aducanumab drug

BBC - 28-Sep-2022

Historic moment for dementia research-large clinical trial to successfully slow cognitive decline

For the first time in 20 years, FDA approved new drug to treat Alzheimer's disease

For the first time in 20 years, FDA approved new drug to treat Alzheimer's disease

BBC - 08-Jun-2021

A long way from a cure, but hopefully indicates that Alzheimer's isn't unassailable

First therapy that could slow Alzheimer's disease

First therapy that could slow Alzheimer's disease

BBC - 22-Oct-2019

Groundbreaking drug is called aducanumab, which targets a protein called amyloid

Biogen's Alzheimer's drug trials halted

Biogen's Alzheimer's drug trials halted

CNN - 21-Mar-2019

Another promising candidate not making it to the finish line

Alzheimer’s progress slowed by plaque-busting drug

Alzheimer’s progress slowed by plaque-busting drug

New Scientist - 25-Mar-2015

In a small trial, the drug slowed the progression of the disease and reduced deposits of amyloid ...

Topics mentioned on this page:
Mental Health, Alzheimer's Disease